Bristol Myers Squibb announced that the European Medicines Agency has validated the extension application to introduce a new route of administration (subcutaneous use) for Opdivo (nivolumab) that includes a new pharmaceutical form and a new strength (600 mg/vial) across multiple previously approved adult solid tumor indications as monotherapy, monotherapy maintenance following completion of nivolumab plus ipilimumab combination therapy, or in combination with chemotherapy or cabozantinib, based on the results from the Phase 3 CheckMate -67T study. Validation of the application confirms the submission is complete and begins the EMA’s centralized review procedure.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMY:
- Bristol Myers says FDA grants accelerated approval of Augtyro
- I-Mab announces clinical trial collaboration with Bristol Myers
- Bristol Myers: Opdivo+Yervoy improved OS vs Lenvatinib or Sorafenib in HCC
- UroGen Pharma announces David Lin as chief commercial officer
- Bristol Myers announces results from Phase 3 KRYSTAL-12 study